Mitapivat PDUFA date

The PDUFA goal date for Mitapivat (AG-348) in sickle cell disease is 1 Feb 2027, as disclosed by Agios Pharmaceuticals, Inc. (AGIO).

PDUFA date
1 Feb 2027
Condition
sickle cell disease

Drug identity checked against registry records

Also recorded as AG-348; AG-348 sulfate hydrate; Mitapivat Sulfate; Mitapivat sulfate

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)NCT07656415AGIOPhase 3Recruiting2029-08Estimated
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension PeriodNCT05144256AGIOPhase 3Active not recruiting2024-05-03Actual
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension PeriodNCT05175105AGIOPhase 3Active not recruiting2024-12-13Actual
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)NCT07506863AGIOPhase 3Recruiting2029-06Estimated
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)NCT04770753AGIOPhase 3Active not recruiting2023-11-13Actual
Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007NCT03853798AGIOPhase 3Completed2024-07-03Actual
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent ThalassemiaNCT07517133AGIOPhase 3Recruiting2029-03Estimated
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)NCT05031780AGIOPhase 2, Phase 3Active not recruiting2025-10-30Actual
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)NCT04770779AGIOPhase 3Active not recruiting2024-04-11Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2027-02-01DayMitapivatAgios Pharmaceuticals, Inc. · AGIOCompany-disclosed PDUFA goal dateAnnounced review targetsickle cell diseaseOpen original source
Read source excerpt

We submitted a supplemental New Drug Application, or sNDA, for the U.S. accelerated approval of mitapivat in sickle cell disease, or SCD, in May 2026, which was accepted with priority review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of November 1, 2026. The PDUFA goal date was subsequently extended to February 1, 2027 following our response to an FDA information request to inform its evaluation as to whether a REMS is necessary for mitapivat in SCD.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

2027-02-01DayMitapivatAgios Pharmaceuticals, Inc. · AGIOCompany-disclosed PDUFA goal dateAnnounced review targetSCDOpen original source
Read source excerpt

We submitted an sNDA for the U.S. accelerated approval of mitapivat in SCD in May 2026, which was accepted with priority review by the FDA and granted a PDUFA goal date of November 1, 2026. The PDUFA goal date was subsequently extended to February 1, 2027 following our response to an FDA information request to inform its evaluation as to whether a REMS is necessary for mitapivat in SCD.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

2027-02-01DayMitapivatAgios Pharmaceuticals, Inc. · AGIOCompany-disclosed PDUFA goal dateAnnounced review targetsickle cell diseaseOpen original source
Read source excerpt

New PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026